Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) EBITDA Margin (2022 - 2025)

Historic EBITDA Margin for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to 155.47%.

  • bioAffinity Technologies' EBITDA Margin fell 732100.0% to 155.47% in Q3 2025 from the same period last year, while for Sep 2025 it was 150.61%, marking a year-over-year decrease of 645300.0%. This contributed to the annual value of 93.9% for FY2024, which is 2117300.0% up from last year.
  • Per bioAffinity Technologies' latest filing, its EBITDA Margin stood at 155.47% for Q3 2025, which was down 732100.0% from 194.65% recorded in Q2 2025.
  • bioAffinity Technologies' EBITDA Margin's 5-year high stood at 79.22% during Q1 2024, with a 5-year trough of 166806.19% in Q1 2023.
  • Moreover, its 4-year median value for EBITDA Margin was 175.06% (2025), whereas its average is 27394.89%.
  • As far as peak fluctuations go, bioAffinity Technologies' EBITDA Margin surged by 1667269700bps in 2024, and later crashed by -1092600bps in 2025.
  • bioAffinity Technologies' EBITDA Margin (Quarter) stood at 68902.77% in 2022, then soared by 100bps to 98.32% in 2023, then tumbled by -34bps to 131.53% in 2024, then dropped by -18bps to 155.47% in 2025.
  • Its EBITDA Margin was 155.47% in Q3 2025, compared to 194.65% in Q2 2025 and 139.37% in Q1 2025.